Medikro to distribute Aerobika* OPEP Devices to patients in Finland and Sweden.

Today Medikro and Trudell Medical International (TMI) announced a distribution agreement to offer TMI’s drug-free Aerobika* OPEP Device to patients in Finland and Sweden. The partnership will expand Medikro’s capabilities to further bolster the management of respiratory conditions, supporting both companies’ shared mission to improve patients’ respiratory health and quality of life.
 

Respiratory Health Challenges
 

Chronic Obstructive Pulmonary Disease (COPD) is a common respiratory disease that causes the lungs to become clogged with phlegm, resulting in restricted airflow and breathing problems. It is the third leading cause of death worldwide. In the EU alone, the European Respiratory Society estimates these conditions account for over 10% of total healthcare spending.¹

Expanding Patient Access to Drug-Free Respiratory Therapy

Medikro is recognized as a leading provider of spirometers and accessories, used to diagnose and monitor COPD. The distribution agreement with TMI will expand their offering to sell the Aerobika* OPEP Device, a drug-free device that uses oscillations and positive expiratory pressure to help open airways and clear excess mucus from the lungs, which can help to improve breathing.^2,3

Value in Partnership

“Medikro’s reputation in the respiratory diagnostic and monitoring field is exceptional” says Cesar Lopez Moreno, TMI’s Vice President of Sales. “It’s a privilege to deliver our device through such trusted experts, helping patients in Finland and Sweden breathe better and live fuller lives.”

“From the outset, our collaboration felt aligned, sharing a common goal to streamline and enrich the treatment pathways for lung diseases.” says Jani Timonen, Head of Product in Medikro.

“Having witnessed Trudell's impactful contributions to respiratory health through their innovative products, our admiration for their expertise, particularly in managing COPD, has only grown,” he says. “Now, as partners, we are privileged to unite our efforts. Together, we are setting new benchmarks for excellence in respiratory care, leveraging our combined strengths to enhance patient outcomes.”

Learn More: Aerobika* OPEP Device
 

Read how the Aerobika* OPEP Device helps patients clear their airways and remove excess mucus: https://www.trudellmed.com/global/en-CA/products/aerobika-opep-device

References
 

1. Forum of International Respiratory Societies. The Global Impact of Respiratory Diseases – Second Ed. Sheffiled, European Respiratory Society, 2017

2. Suggett J. Quality of life responder rate analysis; SGRQ vs CAT assessment. COPD 10, 2016. UK. 

3.Coppolo DP, et al. Plum Ther. 2022 Mar 8: (1): 1-41.